3,688
edits
Cystic Fibrosis: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
Grasemann H, Ratjen F. Cystic Fibrosis. N Engl J Med. 2023 Nov 2;389(18):1693-1707. doi: 10.1056/NEJMra2216474. PMID: 37913507. | Grasemann H, Ratjen F. Cystic Fibrosis. N Engl J Med. 2023 Nov 2;389(18):1693-1707. doi: 10.1056/NEJMra2216474. PMID: 37913507. | ||
Stoltz DA, Meyerholz DK, Welsh MJ: Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372: 351-62 | |||
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA: Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med 2022; 10: 267-277 | |||
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE: Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med 2021; 9: 733-746 | |||
Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D: The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022 | |||
Dagenais RVE, Su VCH, Quon BS: Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med 2020; 10 | |||